Cargando…

A combined regimen of etretinate and UVB modulate T6+ and HLA-DR+ epidermal cells.

Using anti-T6 and anti-HLA-DR monoclonal antibodies, this study was designed to attain what would do to epidermal Langerhans cell (LC) markers in psoriatic patients when two remedies, etretinate and UVB, having controversial effects on LC were put to use simultaneously. In normal and psoriatic subje...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Y. H., Kim, C. W., Houh, W.
Formato: Texto
Lenguaje:English
Publicado: Korean Academy of Medical Sciences 1987
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3053616/
https://www.ncbi.nlm.nih.gov/pubmed/3271057
_version_ 1782199769698926592
author Kim, Y. H.
Kim, C. W.
Houh, W.
author_facet Kim, Y. H.
Kim, C. W.
Houh, W.
author_sort Kim, Y. H.
collection PubMed
description Using anti-T6 and anti-HLA-DR monoclonal antibodies, this study was designed to attain what would do to epidermal Langerhans cell (LC) markers in psoriatic patients when two remedies, etretinate and UVB, having controversial effects on LC were put to use simultaneously. In normal and psoriatic subjects, HLA-DR+ LC was approximately 80% of T6+ LC and a single dose of UVB equivalent to minimal erythema dose (MED), reduced LC membrane markers to approximately 30% of non-irradiated control. The recovery of LC membrane markers, after a single dose of UVB exposure were significantly faster in the group of etretinate treated psoriatic subject than only UVB irradiated psoriatic control. Taken together, seemed to exert prompt recovery of normalization of the number of LC from the depletion following the UVB.
format Text
id pubmed-3053616
institution National Center for Biotechnology Information
language English
publishDate 1987
publisher Korean Academy of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-30536162011-03-16 A combined regimen of etretinate and UVB modulate T6+ and HLA-DR+ epidermal cells. Kim, Y. H. Kim, C. W. Houh, W. J Korean Med Sci Research Article Using anti-T6 and anti-HLA-DR monoclonal antibodies, this study was designed to attain what would do to epidermal Langerhans cell (LC) markers in psoriatic patients when two remedies, etretinate and UVB, having controversial effects on LC were put to use simultaneously. In normal and psoriatic subjects, HLA-DR+ LC was approximately 80% of T6+ LC and a single dose of UVB equivalent to minimal erythema dose (MED), reduced LC membrane markers to approximately 30% of non-irradiated control. The recovery of LC membrane markers, after a single dose of UVB exposure were significantly faster in the group of etretinate treated psoriatic subject than only UVB irradiated psoriatic control. Taken together, seemed to exert prompt recovery of normalization of the number of LC from the depletion following the UVB. Korean Academy of Medical Sciences 1987-06 /pmc/articles/PMC3053616/ /pubmed/3271057 Text en
spellingShingle Research Article
Kim, Y. H.
Kim, C. W.
Houh, W.
A combined regimen of etretinate and UVB modulate T6+ and HLA-DR+ epidermal cells.
title A combined regimen of etretinate and UVB modulate T6+ and HLA-DR+ epidermal cells.
title_full A combined regimen of etretinate and UVB modulate T6+ and HLA-DR+ epidermal cells.
title_fullStr A combined regimen of etretinate and UVB modulate T6+ and HLA-DR+ epidermal cells.
title_full_unstemmed A combined regimen of etretinate and UVB modulate T6+ and HLA-DR+ epidermal cells.
title_short A combined regimen of etretinate and UVB modulate T6+ and HLA-DR+ epidermal cells.
title_sort combined regimen of etretinate and uvb modulate t6+ and hla-dr+ epidermal cells.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3053616/
https://www.ncbi.nlm.nih.gov/pubmed/3271057
work_keys_str_mv AT kimyh acombinedregimenofetretinateanduvbmodulatet6andhladrepidermalcells
AT kimcw acombinedregimenofetretinateanduvbmodulatet6andhladrepidermalcells
AT houhw acombinedregimenofetretinateanduvbmodulatet6andhladrepidermalcells
AT kimyh combinedregimenofetretinateanduvbmodulatet6andhladrepidermalcells
AT kimcw combinedregimenofetretinateanduvbmodulatet6andhladrepidermalcells
AT houhw combinedregimenofetretinateanduvbmodulatet6andhladrepidermalcells